Latest from UC Davis

Karen Kelly, MD, discusses how to determine treatment after patients with lung cancer progress on TKIs.
R. Lor Randall, MD, FACS, discusses ongoing studies and treatment options in the orthopedic oncology landscape.
Jonathan Riess, MD, MS, discusses ongoing research with PARP inhibitors in lung cancer and potential biomarkers for this class of agents.
Richard Bold, MD, chief of the Division of Surgical Oncology, has been named Physician-in-Chief of the UC Davis Comprehensive Cancer Center.
Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the potential role of IDO inhibitors in the treatment of patients with renal cell carcinoma.
Advances in treatment and supportive care have resulted in substantial improvements in cancer survival and a growing number of cancer survivors in the United States.
David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer (IASLC), discusses the Lung Master Protocol (Lung-MAP) Trial and how it is an example of a rational clinical design that will impact patient care. Gandara shared this insight during an interview at the 2016 IASLC Multidisciplinary Symposium on Thoracic Oncology.
David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, UC Davis Health System, discusses the most recent—and significant—advancements in the field of lung cancer.
Publication Bottom Border
Border Publication
x